Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-468 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.7230 | 0.1032 | 0.0343 | 0.5264 | 0.7426 | 0.94963 |
MDA-MB-468 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.016032 | -0.0415 | 0.4371 | 0.1010 | 0.9482 | 0.015849 | 0.98843 |
MDA-MB-468 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.5275 | 0.4288 | 0.0743 | 0.2018 | 1.1048e-05 | 0.70612 |
MDA-MB-468 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.023529 | 0.0573 | 0.5025 | 0.1038 | 1.2151 | 0.020647 | 0.99651 |
MDA-MB-468 | PF-4708671 | p70S6K | PI3K/mTOR | 4.1732 | 0.0813 | 0.1176 | 0.0094 | 1.1782 | 8.8804 | 0.99743 |
MDA-MB-468 | Buparlisib | pan PI3K | PI3K/mTOR | 0.83168 | -0.5157 | 0.3573 | 0.2010 | 2.1267 | 1.1738 | 0.99824 |
MDA-MB-468 | Pictilisib | pan PI3K | PI3K/mTOR | 2.3306 | -0.0613 | 0.2054 | 0.0776 | 0.7959 | 9.2675 | 0.99096 |
MDA-MB-468 | Ceritinib | ALK | RTK | 0.76749 | -0.7415 | 0.4050 | 0.1730 | 1.6622 | 1.3833 | 0.99574 |
MDA-MB-468 | Neratinib | EGFR/HER2 | RTK | 0.15781 | -0.3825 | 0.3861 | 0.1513 | 0.8303 | 0.41607 | 0.99579 |
MDA-MB-468 | Tivantinib | MET | RTK | 0.30706 | -0.4549 | 0.4903 | 0.2341 | 2.9835 | 0.37002 | 0.99499 |
MDA-MB-468 | Cediranib | VEGFR/cKIT | RTK | 3.9154 | -0.7083 | 0.1649 | 0.0970 | 3.0423 | 5.6183 | 0.9962 |
MDA-MB-468 | Cabozantinib | VEGFR2/MET | RTK | 8.9681 | 0.4233 | 0.0441 | 0.0115 | 1.7711 | 16.6732 | 0.9812 |
CAL-51 | Abemaciclib | CDK4/6 | Cell cycle | 0.11268 | -0.4637 | 0.5776 | 0.0890 | 0.4136 | 1.605 | 0.97536 |
CAL-51 | Palbociclib | CDK4/6 | Cell cycle | 0.37241 | 0.3607 | 0.2498 | -0.0215 | 0.8353 | 0.084749 | 0.99265 |
CAL-51 | AZD7762 | CHK1/2 | Cell cycle | 0.044603 | -0.5186 | 0.7151 | 0.2631 | 1.2331 | 0.070405 | 0.98322 |
CAL-51 | Volasertib | PLK | Cell cycle | 0.0059136 | -0.3372 | 0.6787 | 0.2411 | 3.0715 | 0.0068268 | 0.99697 |
CAL-51 | Dinaciclib | pan CDK | Cell cycle | 0.014709 | -0.3585 | 0.5985 | 0.2374 | 3.5319 | 0.017105 | 0.99939 |
CAL-51 | Cisplatin | Chemo | Chemotherapy | 2.0989 | -0.0329 | 0.2145 | 0.0322 | 0.9070 | 4.8677 | 0.9969 |
CAL-51 | Doxorubicin | Chemo | Chemotherapy | 0.0085841 | -0.4803 | 0.7954 | 0.2347 | 1.0881 | 0.014188 | 0.98761 |
CAL-51 | Taxol | Chemo | Chemotherapy | 0.004167 | -0.2200 | 0.6694 | 0.1963 | 1.3689 | 0.0053072 | 0.99639 |
CAL-51 | Topotecan | Topo I | Chemotherapy | 0.019146 | -0.5303 | 0.8558 | 0.2745 | 1.1807 | 0.031097 | 0.97872 |
CAL-51 | Etoposide | Topo II | Chemotherapy | 0.24029 | -0.2097 | 0.4669 | 0.0707 | 1.1885 | 0.32971 | 0.99772 |
CAL-51 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.058089 | 0.0983 | 0.5161 | 0.1625 | 0.8670 | 0.042316 | 0.9975 |
CAL-51 | Trametinib | MEK | MAPK/nRTK | Inf | 0.7064 | 0.0662 | 0.0124 | 0.8944 | 0.19105 | 0.98439 |
CAL-51 | Saracatinib | SRC | MAPK/nRTK | 1.8499 | 0.2582 | 0.2271 | 0.0547 | 0.6810 | 1.6055 | 0.99804 |